293306-64-6Relevant academic research and scientific papers
Synthesis of 2,4- and 2,5-disubstituted oxazoles via metal-catalyzed cross-coupling reactions
Counceller, Carla M.,Eichman, Chad C.,Proust, Nicolas,Stambuli, James P.
supporting information; experimental part, p. 79 - 83 (2011/03/23)
The rapid synthesis of 2,4- and 2,5-disubstituted oxazoles via metal-catalyzed cross-coupling reactions is reported. The 4- or 5-position of the corresponding 4- or 5-halogenated 2-butylthiooxazoles was successfully functionalized via Suzuki-Miyaura, Sono
Palladium- and nickel-catalyzed direct alkylation of azoles with unactivated alkyl bromides and chlorides
Yao, Tomoyuki,Hirano, Koji,Satoh, Tetsuya,Miura, Masahiro
scheme or table, p. 12307 - 12311 (2011/02/16)
Long-ing alkyl chain: The catalytic direct C-H alkylation of azoles with unactivated alkyl bromides and chlorides is described. A palladium catalyst enables the alkylation of oxazoles, whereas a nickel one shows unique activity for thiazole. The catalyses allow a straightforward access to azole motifs bearing long, functional alkyl side chains.
Substituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonists
Ok,Reigle,Candelore,Cascieri,Colwell,Deng,Feeney,Forrest,Hom,MacIntyre,Strader,Tota,Wang,Wyvratt,Fisher,Weber
, p. 1531 - 1534 (2007/10/03)
As a part of our investigation into the development of orally bioavailable β3 adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent β3 agonists with excellent selectivity against other β receptors. Several of these compounds showed excellent oral bioavailability in dogs. One example, cyclopentylethyloxazole 5f is a potent β3 agonist (EC50 = 14 nM, 84% activation) with 340-fold and 160-fold selectivity over β1 and β2 receptors, respectively, and has 38% oral bioavailability in dogs. (C) 2000 Elsevier Science Ltd. All rights reserved.
